MDT-AP-2615
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 26.64
- os_event
- false
- age_years
- 6
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.987018767
- umap2_2d
- 2.652361137
- umap1_3d
- 2.400861953
- umap2_3d
- -1.497751293
- umap3_3d
- -1.225935131
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.260
- PANCREAS_BETA_CELLS+0.220
- DNA_REPAIR+0.190
- SPERMATOGENESIS+0.190
- OXIDATIVE_PHOSPHORYLATION+0.120
- E2F_TARGETS+0.100
- ESTROGEN_RESPONSE_LATE+0.080
- XENOBIOTIC_METABOLISM+0.060
- HEME_METABOLISM+0.050
- APICAL_SURFACE+0.030
Top 10 suppressed
- TGF_BETA_SIGNALING-0.500
- ANGIOGENESIS-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- INFLAMMATORY_RESPONSE-0.390
- UV_RESPONSE_DN-0.390
- IL6_JAK_STAT3_SIGNALING-0.360
- TNFA_SIGNALING_VIA_NFKB-0.360
- COMPLEMENT-0.340
- ALLOGRAFT_REJECTION-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2074 | Med | Medulloblastoma | 0.919 |
| 2 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.899 |
| 3 | TCGA-XF-A8HC-01A-11R-A36F-07 | — | — | 0.890 |
| 4 | TCGA-E5-A4U1-01A-11R-A31N-07 | — | — | 0.871 |
| 5 | s0112301 | — | — | 0.861 |
| 6 | TCGA-53-A4EZ-01A-12R-A24X-07 | — | cohortA3 | 0.856 |
| 7 | TCGA-LT-A5Z6-01A-11R-A28M-07 | — | — | 0.849 |
| 8 | MDT-AP-1131 | Med | Medulloblastoma | 0.847 |
| 9 | MDT-AP-1302 | Med | Medulloblastoma | 0.846 |
| 10 | R70 | — | — | 0.846 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.190 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |